Status:
UNKNOWN
Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease?
Lead Sponsor:
Marie Luise Bisgaard, MD
Conditions:
Von Hippel-Lindaus Disease
Eligibility:
All Genders
18+ years
Brief Summary
The investigators aim to analyze tumors from vHL patients who have different courses of disease and different types of VHL gene alterations to characterize which types of genetic alterations the tumor...
Detailed Description
In vHL tumors from patients with different phenotypes and different genetic backgrounds, the investigators aim to assess both the nature of germline and somatic VHL mutations along with the total resi...
Eligibility Criteria
Inclusion
- vHL diagnosed in patient
- Patient over 18 years of age
- Informed consent to participate can be obtained
- Patient has had at least one vHL-related tumor removed
- A reference DNA sample (from blood or normal tissue) and tumor tissue (paraffin-embedded or fresh frozen) can be obtained.
Exclusion
- Patients under the age of 18 years
- Patients who had not previously had a vHL-related tumor removed
- Patients whos previously removed tumor tissue cannot be obtained or is of such a quantity or quality that no exact histological analysis can be done and/or no DNA can be extracted
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2017
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02207686
Start Date
September 1 2014
End Date
August 1 2017
Last Update
November 13 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cellular and Molecular Medicine, University of Copenhagen
Copenhagen, Copenhagen N, Denmark, DK-2200